CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Clinical Cancer Research

• Publication date

  2006-02-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-05-2018PMID 16489096
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Annual Report to the Nation on the Status of Cancer, 1975–2005, Featuring Trends in Lung Cancer, Tobacco Use, and Tobacco Control

  2008cited by this paper
• Response of human tumor xenografts in athymic nude mice to docetaxel (RP 56976, Taxotere®)

  2007cited by this paper
• Therapeutic Monoclonal Antibodies in Oncology

  2005cited by this paper
• Management of cutaneous melanoma.

  2004cited by this paper
• HMB-45, S-100, NK1/C3, and MART-1 in metastatic melanoma.

  2004cited by this paper
• Annual report to the nation on the status of cancer, 1975–2001, with a special feature regarding survival

  2004cited by this paper
• Non-small-cell lung cancer molecular signatures recapitulate lung developmental pathways.

  2003cited by this paper
• Development of potent monoclonal antibody auristatin conjugates for cancer therapy

  2003cited by this paper
• Development of potent monoclonal antibody auristatin conjugates for cancer therapy

  2003cited by this paper
• Therapeutic antibodies for human diseases at the dawn of the twenty-first century

  2003cited by this paper
• Osteoactivin expressed during cirrhosis development in rats fed a choline-deficient, L-amino acid-defined diet, accelerates motility of hepatoma cells.

  2003cited by this paper
• Bone-related Genes Expressed in Advanced Malignancies Induce Invasion and Metastasis in a Genetically Defined Human Cancer Model*

  2003cited by this paper
• Molecular characterisation of soft tissue tumours: a gene expression study.

  2002cited by this paper
• Immunotherapy for melanoma.

  2002cited by this paper
• Improving the efficacy of antibody-based cancer therapies

  2001cited by this paper
• Cloning and characterization of osteoactivin, a novel cDNA expressed in osteoblasts

  2001cited by this paper
• Expression of gp100, MART‐1, tyrosinase, and S100 in paraffin‐embedded primary melanomas and locoregional, lymph node, and visceral metastases: implications for diagnosis and immunotherapy. A study conducted by the EORTC Melanoma Cooperative Group

  2001cited by this paper
• Ultraviolet A and melanoma: a review.

  2001cited by this paper
• Molecular Cloning of a Dendritic Cell-associated Transmembrane Protein, DC-HIL, That Promotes RGD-dependent Adhesion of Endothelial Cells through Recognition of Heparan Sulfate Proteoglycans*

  2001cited by this paper
• The AP-3-dependent targeting of the melanosomal glycoprotein QNR-71 requires a di-leucine-based sorting signal.

  2001cited by this paper
• Identifying potential tumor markers and antigens by database mining and rapid expression screening.

  2000cited by this paper
• Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy.

  1999cited by this paper
• Heterogeneous expression of melanoma‐associated antigens and HLA‐A2 in metastatic melanoma in vivo

  1998cited by this paper
• Cathepsin B-sensitive dipeptide prodrugs. 2. Models of anticancer drugs paclitaxel (Taxol), mitomycin C and doxorubicin.

  1998cited by this paper
• Human antibodies by design

  1998cited by this paper
• Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group.

  1997cited by this paper
• Characterization of a new melanocyte‐specific gene (QNR‐71) expressed in v‐myc‐transformed quail neuroretina.

  1996cited by this paper
• Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha.

  1996cited by this paper
• Metastatic potential of human melanoma cells in nude mice--characterisation of phenotype, cytokine secretion and tumour-associated antigens.

  1996cited by this paper
• nmb, a novel gene, is expressed in low‐metastatic human melanoma cell lines and xenografts

  1995cited by this paper
• Systemic treatments for advanced cutaneous melanoma.

  1995cited by this paper
• Role of recombinant interleukin-2 in combination with interferon-alfa and chemotherapy in the treatment of advanced melanoma.

  1993cited by this paper
• Antigen expression of metastasizing and non-metastasizing human melanoma cells xenografted into nude mice

  1991cited by this paper
• Molecular characterisation of soft tissue tumours : a gene expression study

  year unknowncited by this paper

• Combining information on degradomics and gene expression data in prospecting metastatic melanoma proteolytic signatures.

  2025cites this paper
• Glycoprotein nonmetastatic melanoma protein B is regulated by hepatic peroxisome proliferator-activated receptor γ in liver steatosis.

  2025cites this paper
• The janus-faced biology of GPNMB: from tissue homeostasis to cancer pathogenesis

  2025cites this paper
• Breaking the Mold: Trailblazing Melanoma Therapy Beyond Checkpoint Through Innovative Approaches.

  2024cites this paper
• GPNMB promotes tumor growth and is a biomarker for lymphangioleiomyomatosis.

  2024cites this paper
• Multiomics integration-based immunological characterizations of adamantinomatous craniopharyngioma in relation to keratinization

  2024cites this paper
• Antibody–Drug Conjugates in the Pipeline for Treatment of Melanoma: Target and Pharmacokinetic Considerations

  2024influential citation
• Tumor associated microglia/macrophages utilize GPNMB to promote tumor growth and alter immune cell infiltration in glioma

  2024cites this paper
• Identification of GPNMB in endometrial cancer based on pan-cancer analysis and in vitro validation

  2024cites this paper
• Human Antibody VH Domains Targeting GPNMB and VCAM-1 as Candidate Therapeutics for Cancers

  2023cites this paper
• Downregulation of Tumor Promotor Genes in Oryza Sativa Linn.-Induced Antiproliferative Activity of Human Squamous Carcinoma Cells

  2023cites this paper
• High-throughput and targeted drug screens identify pharmacological candidates against MiT-translocation renal cell carcinoma

  2023influential citation
• Monomethyl auristatin antibody and peptide drug conjugates for trimodal cancer chemo-radio-immunotherapy

  2022cites this paper
• HSP90 inhibitors induce GPNMB cell-surface expression by modulating lysosomal positioning and sensitize breast cancer cells to glembatumumab vedotin

  2022cites this paper
• Antibody–Drug Conjugates as an Emerging Therapy in Oncodermatology

  2022influential citation
• Glycoprotein NMB promotes tumor formation and malignant progression of laryngeal squamous cell carcinoma

  2022cites this paper
• [89Zr]ZrDFO-CR011 positron emission tomography correlates with response to glycoprotein non-metastatic melanoma B-targeted therapy in triple negative breast cancer.

  2022cites this paper
• N‐glycosylated GPNMB ligand independently activates mutated EGFR signaling and promotes metastasis in NSCLC

  2021cites this paper
• Expression pattern and prognostic impact of glycoprotein non-metastatic B (GPNMB) in triple-negative breast cancer

  2021cites this paper
• Considerations for the Nonclinical Safety Evaluation of Antibody–Drug Conjugates

  2021cites this paper
• Functional characterization of Gpnmb in inflammatory and metabolic diseases

  2020cites this paper
• New Emerging Biotherapies

  2020cites this paper
• GPNMB is expressed in human epidermal keratinocytes but disappears in the vitiligo lesional skin

  2020cites this paper
• Antibody Based Targeted Interventions for the Diagnosis and Treatment of Skin Cancers.

  2020cites this paper
• Genomic Complexity of Osteosarcoma and Its Implication for Preclinical and Clinical Targeted Therapies.

  2020cites this paper
• A Phase II Study of Glembatumumab Vedotin for Metastatic Uveal Melanoma

  2020cites this paper
• Prognostic values of GPNMB identified by mining TCGA database and STAD microenvironment

  2020cites this paper
• Glioblastoma and malignant melanoma: Serendipitous or anticipated association?

  2020influential citation
• Antibody-drug conjugates: an evolving approach for melanoma treatment.

  2020cites this paper
• Current Development of Monoclonal Antibodies in Cancer Therapy.

  2020cites this paper
• Clinical and Molecular Characterization of Microphthalmia-Associated Transcription Factor (MITF)-Related Renal Cell Carcinoma.

  2020cites this paper
• 111In-Labeled Glycoprotein Nonmetastatic b (GPNMB) Targeted Gemini Surfactant-Based Nanoparticles against Melanoma: In Vitro Characterization and in Vivo Evaluation in Melanoma Mouse Xenograft Model.

  2019cites this paper
• Towards new personalized treatment options for patients with genomically unstable tumors

  2019cites this paper
• A phase 2 study of glembatumumab vedotin, an antibody‐drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma

  2019cites this paper
• Development of a Reproducible Prognostic Gene Signature to Predict the Clinical Outcome in Patients with Diffuse Large B-Cell Lymphoma

  2019cites this paper
• The Differentially Expressed Genes of Human Sporadic Cerebral Cavernous Malformations.

  2018cites this paper
• University of Groningen Glioma-Associated Microglia / Macrophages Display an Expression Profile Different from M 1 and M 2 Polarization and Highly Express Gpnmb and Spp 1

  2018cites this paper
• Data-Driven prioritisation of antibody-drug conjugate targets in head and neck squamous cell carcinoma.

  2018cites this paper
• Natural Product Synthesis for Drug Discovery and Chemical Biology

  2018cites this paper
• Glycoprotein nmb Is Exposed on the Surface of Dormant Breast Cancer Cells and Induces Stem Cell-like Properties.

  2018cites this paper
• Clinical Significance of Glycoprotein Non-metastatic B and Its Association with EGFR/HER2 in Gastrointestinal Cancer

  2018cites this paper
• Blocking Monocytic Myeloid-Derived Suppressor Cell Function via Anti-DC-HIL/GPNMB Antibody Restores the In Vitro Integrity of T Cells from Cancer Patients

  2018cites this paper
• Integrated analysis of fine-needle-aspiration cystic fluid proteome, cancer cell secretome, and public transcriptome datasets for papillary thyroid cancer biomarker discovery

  2018cites this paper
• Osteoactivin regulates head and neck squamous cell carcinoma invasion by modulating matrix metalloproteases

  2018influential citation
• Antibody–Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments

  2017cites this paper
• BIOLOGICAL ROLE OF OSTEOACTIVIN, A PROTEIN EXPRESSED BY TUMOR-CONDITIONED MACROPHAGES, IN THE PROCESSES OF TUMOR GROWTH AND TISSUE REPAIR

  2017cites this paper
• GPNMB Induces BiP Expression by Enhancing Splicing of BiP Pre-mRNA during the Endoplasmic Reticulum Stress Response

  2017cites this paper
• Glycoprotein Non‐Metastatic Melanoma Protein B (GPNMB) and Cancer: A Novel Potential Therapeutic Target

  2017influential citation
• Preclinical PET imaging of glycoprotein non-metastatic melanoma B in triple negative breast cancer: feasibility of an antibody-based companion diagnostic agent

  2017cites this paper
• Targeting GPNMB with glembatumumab vedotin: Current developments and future opportunities for the treatment of cancer☆

  2017influential citation
• Knocking down glycoprotein nonmetastatic melanoma protein B suppresses the proliferation, migration, and invasion in bladder cancer cells

  2017cites this paper
• Marine Antibody–Drug Conjugates: Design Strategies and Research Progress

  2017cites this paper
• CANCER CELL TARGETING: WHY ARE SO FEW ANTIBODY-DRUG CONJUGATES FDA APPROVED?

  2017influential citation
• Novel Targeted Therapies for Metastatic Melanoma

  2017cites this paper
• The transcription factor MAFK induces EMT and malignant progression of triple-negative breast cancer cells through its target GPNMB

  2017cites this paper
• Proteomic changes in cerebrospinal fluid from primary central nervous system lymphoma patients are associated with protein ectodomain shedding

  2017cites this paper
• The Linker Approach

  2017cites this paper
• Inhibition of Phosphatase Activity Follows Decline in Sulfatase Activity and Leads to Transcriptional Effects through Sustained Phosphorylation of Transcription Factor MITF

  2016cites this paper
• Antibody‐Drug Conjugates: A Clinical Pharmacy Perspective on an Emerging Cancer Therapy

  2016cites this paper
• Gpnmb/osteoactivin: an indicator and therapeutic target in tumor and nontumorous lesions.

  2016cites this paper
• Targeting Glycoprotein NMB With Antibody‐Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma

  2016cites this paper
• Novel melanoma therapy

  2016cites this paper
• Osteoactivin Promotes Migration of Oral Squamous Cell Carcinomas

  2016influential citation
• Prospects of osteoactivin in tissue regeneration

  2016cites this paper
• Drugs and Drug Candidates from Marine Sources: An Assessment of the Current “State of Play”

  2016cites this paper
• Imagerie photoacoustique couplée à l’échographie haute résolution et à la fluorescence infrarouge en oncologie préclinique translationnelle

  2016cites this paper
• Engineered cytokine derivatives for targeted cancer immunotherapy

  2016cites this paper
• Minireview: Lymphangioleiomyomatosis (LAM): The "Other" Steroid-Sensitive Cancer.

  2016cites this paper
• Estrogen maintains myometrial tumors in a lymphangioleiomyomatosis model.

  2016cites this paper
• The Potential Role of the Glycoprotein Osteoactivin/Glycoprotein Nonmetastatic Melanoma Protein B in Pancreatic Cancer

  2015cites this paper
• The marine origin of drugs

  2015cites this paper
• The effect of GPNMB on muscular atrophy caused by ALS

  2015cites this paper
• Toxicities Associated with Antibody Drug Conjugates

  2015cites this paper
• Preclinical Childhood Sarcoma Models: Drug Efficacy Biomarker Identification and Validation

  2015cites this paper
• Formulation Development for Antibody-Drug Conjugates

  2015cites this paper
• Novel Therapies on the Horizon

  2015cites this paper
• Antibody-Drug Conjugates

  2015cites this paper
• Glioma-Associated Microglia/Macrophages Display an Expression Profile Different from M1 and M2 Polarization and Highly Express Gpnmb and Spp1

  2015cites this paper
• Emerging formats for next-generation antibody drug conjugates

  2015influential citation
• Targeted delivery of immunomodulatory proteins: evaluation of novel antibody-chemokine and antibody-cytokine fusion proteins for cancer therapy

  2015cites this paper
• The Antibody-Drug Conjugate Glembatumumab Vedotin (CDX-011) and Its Use in Treatment of Breast Cancer

  2015cites this paper
• Glycoprotein nonmetastatic melanoma protein B ameliorates skeletal muscle lesions in a SOD1G93A mouse model of amyotrophic lateral sclerosis

  2015cites this paper
• EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer.

  2015cites this paper
• Potential Therapeutic Targets in Triple Negative Breast Cancer

  2015cites this paper
• Role of inflammation in the aging bones.

  2015cites this paper
• Glycoprotein nonmetastatic B as a prognostic indicator in small cell lung cancer

  2014cites this paper
• Serum Cytokine Profile in Patients With Pancreatic Cancer

  2014cites this paper
• Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma.

  2014cites this paper
• GPNMB/OA protein increases the invasiveness of human metastatic prostate cancer cell lines DU145 and PC3 through MMP-2 and MMP-9 activity.

  2014cites this paper
• Initial testing (stage 1) of glembatumumab vedotin (CDX‐011) by the pediatric preclinical testing program

  2014cites this paper
• Glycoprotein nonmetastatic melanoma protein B (GPNMB) as a novel neuroprotective factor in cerebral ischemia-reperfusion injury.

  2014cites this paper
• Emerging classes of armed antibody therapeutics against cancer

  2014cites this paper
• Identification of novel inflammatory serum biomarker signatures associated with pancreatic cancer and molecular characterization of antitumour agents over proliferation and apoptosos in vitro

  2014influential citation
• Marine-Sourced Anti-Cancer and Cancer Pain Control Agents in Clinical and Late Preclinical Development †

  2014cites this paper
• Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer.

  2014cites this paper
• Rage (Receptor for Advanced Glycation End Products) in Melanoma Progression

  2014cites this paper
• Glycoprotein non-metastatic melanoma protein B as a predictive prognostic factor in clear-cell renal cell carcinoma following radical nephrectomy.

  2014cites this paper
• Management of Metastatic Breast Cancer with Second-Generation Antibody–Drug Conjugates: Focus on Glembatumumab Vedotin (CDX-011, CR011-vcMMAE)

  2014influential citation
• Antibody-drug conjugate (ADC) clinical pipeline: a review.

  2013cites this paper
• A similarity in peptide cross-reactivity between alloantigen- and nominal antigen-induced CD8+ T cell responses in vitro

  2013cites this paper